Parkinson's disease, CYP2D6 polymorphism, and age

Neurology

Volumn 56, Issue 10, 2001, Pages 1363-1370

  Payami, Haydeh ^a,b   Lee, N ^a   Zareparsi, S ^a   Gonzales McNeal, M ^b   Camicioli, R ^a   Bird, T D ^e   Sexton, G ^b   Gancher, S ^d   Kaye, J ^a,c   Calhoun, D ^a   Swanson, P D ^e   Nutt, J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CYP2D6 GENE; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL;

EID: 0035933142     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.10.1363     Document Type: Article

References (54)

1. Payami H, Zareparsi S. Genetic epidemiology of Parkinson's disease. J Geriatr Psychiatry Neurol 1998;11:98-106.
2. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
3. Zareparsi S, Kaye J, Camicioli R, et al. Analysis of the a-synuclein G209A mutation in familial Parkinson's disease. Lancet 1998;351:37.
4. Vaughan JR, Farrer MJ, Wszolek ZK, et al. Sequencing of the α-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. Hum Mol Genet 1998;7:751-753.
5. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
6. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560-1567.
7. Payami H, Larsen K, Bernard S, et al. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 1994;36:659-661.
8. Lazzarini AM, Myers RH, Zimmerman TR, et al. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology 1994;44:499-506.
9. Marder K, Tang M-X, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 1996;47:155-160.
10. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14:317-335.
11. Langston JW, Ballard P, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
12. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.
13. Daly AK, Brockmoller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
14. Gilham DE, Cairns W, Paine MJI, et al. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997;27:111-125.
15. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998;249: 838-843.
16. Barbeau A, Cloutier T, Roy M, et al. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985;2: 1213-1216.
17. McCann SJ, Pond SM, James KM, et al. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci 1997;153:50-53.
18. Rostami-Hodjegan A, Lennard MS, Woods HF, et al. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 1998; 8:227-238.
19. Armstrong M, Daly AK, Cholerton S, et al. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
20. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
21. 450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993;48:166-168.
22. Rempfer R, Crook R, Houlden H, et al. Parkinson's disease, but not Alzheimer's disease, Lewy body variant associated with mutant alleles at cytochrome P450 gene. Lancet 1994; 344:815.
23. Plante-Bordeneuve V, Davis MB, Maraganore DM, et al. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57:911-913.
24. Agundez JAG, Jimenez-Jimenez FJ, Luengo A, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995;57:291-298.
25. Sandy MS, Armstrong M, Tanner CM, et al. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 1996;47:225-230.
26. Lucotte G, Turpin J-C, Gerard N, et al. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families. Am J Med Genet 1996;67:361-365.
27. Diederich N, Hilger C, Goetz CG, et al. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996;40:463-465.
28. Bordet R, Broly F, Destee A, et al. Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease. Clin Neuropharmacol 1996;19: 213-221
29. Gasser T, Muller-Myhsok B, Supala A, et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:518-520.
30. De Palma G, Mozzoni P, Mutti A, et al. Case-control study of interactions between genetic and environmental factors in Parkinson's disease. Lancet 1998;352:1986-1987.
31. Atkinson A, Singleton AB, Steward A, et al. CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease. Pharmacogenetics 1999; 9:31-35.
32. Bon MAM, Jansen Steur ENH, de Vos RAI, et al. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism. Neurosci Lett 1999;266:149-151.
33. Sabbagh N, Brice A, Marez D, et al. CYP2D6 polymorphism and Parkinson's disease susceptibility. Mov Disord 1999;14: 230-236.
34. Joost O, Taylor CA, Thomas CA, et al. Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease. Mov Disord 1999;14:590-595.
35. Nicholl DJ, Bennett P, Hiller L, et al. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Neurology 1999;53:1415-1421.
36. Maraganore DM, Farrer MJ, Hardy JA, et al. Case-control study of debrisoquin E 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease. Mov Disord 2000;15:714-719.
37. Zareparsi S, Taylor TD, Harris EL, et al. Segregation analysis of Parkinson disease. Am J Med Genet 1998;80:410-417.
38. Zareparsi S, Kaye J, Camicioli R, et al. Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Ann Neurol 1997;42:655-658.
39. Kruger R, Vieira-Saecker AMM, Kuhn W, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined α-synuclein/apolipoprotein E genotype. Ann Neurol 1999;45:611-617.
40. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
41. Agundez JAG, Martinez C, Ledesma MC, et al. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 1994; 55:412-417.
42. Aynacioglu A, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999;66:185-192.
43. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-408.
44. Payami H, Grimslid H, Oken B, et al. A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. Am J Hum Genet 1997;60:948-956.
45. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
46. Kaplan E, Meier EL. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-481.
47. Wanwimolruk S, Bhawan S, Coville PF, et al. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Eur J Clin Pharmacol 1998;54:431-5.
48. Yamada H, Dahl M-L, Lannfelt L, et al. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 1998;54:479-481.
49. Bathum L, Andersen-Ranberg K, Boldsen J, et al. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. Eur J Clin Pharmacol 1998;54:427-430.
50. Muiras M, Verasdonck P, Cottet F, et al. Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci. Hum Genet 1998;102:526-532.
51. Agundez JAG, Rodriguez I, Olivera M, et al. CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing 1997;26:147-151.
52. Vincent-Viry M, Muller J, Fournier B, et al. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population. Clin Chem 1991;37:327-332.
53. Poirier J, Roy M, Campanella G, Cloutier T, et al. Debrisoquine metabolism in parkinsonian patients treated with anti-histamine drugs. Lancet 1987;2:386.
54. Vincent-Viry M, Fournier B, Galteau MM. Short communication. The effects of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab Dispos 2000;28:617-619.